Outcomes for Patients with Non-metastatic Triple-negative Breast Cancer in New Zealand

James, Melissa; Dixit, Ashutosh; Robinson, Bridget A.; Frampton, Christopher; Davey, Valerie

doi:10.1016/j.clon.2018.09.006

Cited by 23 publications

(29 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Doxorubicin is used in about 78% TNBC patients, while paclitaxel in 49% of the patients. 40 The three drugs are general cytotoxic with an almost similar mechanism of action. The drugs kill cancer cells by inducing DNA damage, promoting apoptosis, and disrupting cell cycle.…”

Section: Discussionmentioning

confidence: 99%

<p>TGF-β-Induced TMEPAI Attenuates the Response of Triple-Negative Breast Cancer Cells to Doxorubicin and Paclitaxel</p>

Wardhani¹,

Puteri²,

Watanabe³

et al. 2020

JEP

View full text Add to dashboard Cite

Purpose: Triple-negative breast cancer (TNBC) is a refractory type of breast cancer with poor prognosis and limited choice for treatment. Previous studies had shown that TNBC has high expressions of transmembrane prostate androgen-induced protein (TMEPAI). TMEPAI was known to be induced by TGF-β/Smad signaling and have tumorigenic functions that converting TGF-β from tumor suppressor to tumor promoter and inducing epithelialmesenchymal transition (EMT). Therefore, we aimed to define the role of TMEPAI in triple-negative breast cancer cells treatment using several anti-cancers in the presence of TGF-β. Methods: TMEPAI-knock out (KO) was carried out in a triple-negative breast cancer cell, BT549. TMEPAI editing was developed using the CRISPR-Cas9 system using two combinations of sgRNA to remove exon 4 of the TMEPAI gene entirely. Genotyping and proteomic analysis were performed to check the establishment of the TMEPAI-KO cells. Wild type (WT) and KO cells were used to determine inhibitory concentration 50% (IC 50) of several anti-cancers: doxorubicin, cisplatin, paclitaxel, and bicalutamide in the presence of TGF-β treatment. Results: KO cells were successfully established by completely removing the TMEPAI gene, which was proven in genomic and proteomic analysis. Further, in TMEPAI-KO cells, we found a significant reduction of IC 50 for doxorubicin and paclitaxel, and minimal effects were seen for cisplatin and bicalutamide. Our findings suggest that TGF-β-induced TMEPAI attenuates the response of TNBC to doxorubicin and paclitaxel, but not to cisplatin and bicalutamide. Conclusion: TGF-β induced TMEPAI contributes to the reduced response of TNBC treatment to doxorubicin and paclitaxel, but minimal on cisplatin and bicalutamide. Further study is needed to confirm our findings in other growth factor-induced cells, as well as in in vivo model.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>TGF-β-Induced TMEPAI Attenuates the Response of Triple-Negative Breast Cancer Cells to Doxorubicin and Paclitaxel</p>

Wardhani¹,

Puteri²,

Watanabe³

et al. 2020

JEP

View full text Add to dashboard Cite

show abstract

“…This is in concordance to previous findings which reported a 68%-82% 5-year survival for TNBC patients. [23][24][25] TNBC patients are four times more likely to develop visceral metastases in contrast to non-TNBC subtype. 26 In addition, the treatment decision for metastatic TNBC is also challenging due to the lack of targeted therapy.…”

Section: Discussionmentioning

confidence: 99%

Breast cancer survivorship in an Asian specialist centre from Malaysia: A retrospective analysis

Ahmad¹,

Tan²,

Manivannan³

et al. 2019

Asian J Med Sci

View full text Add to dashboard Cite

Background: Real world data (RWD) is increasingly relevant in breast cancer (BCa) as it is the most frequently diagnosed cancer. Developed world has seen improved breast cancer survival, however, RWDon BCa survival in Malaysia is still lacking. Aims and Objectives: This study aims to determine characteristics and survival of BCa patients from a single institute. Materials and Methods: Retrospective analysis of 168 BCa patients who were treated with at least one treatment modality in Beacon International Specialist Centre (BISC) from 2008-2012 was conducted. Patient characteristicsand treatments received were analysed descriptively to survival outcome.Vital status was obtained from the National Registry of Birth and Death (NRD) records. Observed survival rates wereestimated by Kaplan-Meier method and difference between groups by log-rank. Results: Of 143 eligible BCa patients,28 (19.6%) died during the study period. Five-year BCa specific survival rates were 100% for Stage I and II, 79.31% for stage III and 38.89% for Stage IV disease. In the multivariate analysis, higher stage at diagnosis, triple negative breast cancer with metastases and higher grade were associated with worse survival outcomes. The overall 5-year survival rate of BCa patients in BISC from 2008-2012 compares favourably to the survival data of developed countries. Conclusion: In conclusion, the overall 5-year survival rate of BCa patients in BISC compares favourably to the survival data of developed countries, as well as to other institutions.

show abstract

“…The cPR rate in BRCA1/2-negative patients with TNBC to neoadjuvant therapy based on carboplatin is higher than that in HER2-positive patients with BC (16). Recurrence occurs, on average, after 1.6 years, with a recurrence rate of 25% in patients with TNBC, 74% of which is systemic recurrence (17). Among recurrent cases, 51% have distant metastases in multiple sites, most frequently in the lung (56%), bone (44%), liver (30%) and brain (22%) (17).…”

Section: Circulating Micrornas and Their Role In The Immune Response mentioning

confidence: 97%

“…Recurrence occurs, on average, after 1.6 years, with a recurrence rate of 25% in patients with TNBC, 74% of which is systemic recurrence (17). Among recurrent cases, 51% have distant metastases in multiple sites, most frequently in the lung (56%), bone (44%), liver (30%) and brain (22%) (17). This highlights the importance of identifying biomarkers to predict recurrence and metastasis as this may improve treatments and prognoses, thus increasing survival rates and times.…”

Section: Circulating Micrornas and Their Role In The Immune Response mentioning

confidence: 99%

Circulating microRNAs and their role in the immune response in triple‑negative breast cancer (Review)

2020

View full text Add to dashboard Cite

Breast cancer (BC) is the most common type of cancer in women worldwide, and despite advances in treatments, its incidence and mortality are increasing. Therefore, it is necessary to develop new, non-invasive tests that provide more accurate diagnosis and prognosis in a timely manner. A promising approach is measuring the presence of biomarkers to detect tumors at various stages and determine their specific characteristics, thus allowing for more personalized treatment. MicroRNAs (miRNAs) serve a role in gene expression, primarily by interacting with messenger RNAs, and may be potential biomarkers for detecting cancer. They are detectable in tissues and blood, including plasma and/or serum, are stable and often tumor specific. Also, different miRNAs are associated with specific BC molecular subtypes. Triple-negative BC (TNBC) is a type of BC in which the primary targets for hormonal therapy are absent. It is an aggressive phenotype, which frequently metastasizes and is associated with an unfavorable prognosis. The present review focuses on circulating miRNAs in patients with TNBC, with an emphasis on their interaction with the immune response checkpoint genes PD-1, PD-L1 and CTLA4. Modulation and response of the immune system are of interest in cancer treatment due to the success of immunotherapy in the treatment of various neoplasms. Based on the findings of this literature review and the in silico analysis performed as part of this review, it is concluded that circulating hsa-miR-195 and hsa-miR-155 in TNBC interact with checkpoint genes involved in the immune response. Further analysis of the expression of these circulating miRNAs and their association with prognosis in patients with TNBC treated with immunotherapy should be assessed to evaluate their possible use as non-invasive predictive biomarkers. In addition, functional studies to analyze biologically relevant targets in the development and prognosis of TNBC, which could be therapeutic targets, are also recommended. Contents 1. Introduction 2. miRNAs as biomarkers in BC 3. Circulating miRNAs in BC 4. Checkpoints and miRNAs in TNBC 5. Conclusions

show abstract

Outcomes for Patients with Non-metastatic Triple-negative Breast Cancer in New Zealand

Cited by 23 publications

References 18 publications

<p>TGF-β-Induced TMEPAI Attenuates the Response of Triple-Negative Breast Cancer Cells to Doxorubicin and Paclitaxel</p>

<p>TGF-β-Induced TMEPAI Attenuates the Response of Triple-Negative Breast Cancer Cells to Doxorubicin and Paclitaxel</p>

Breast cancer survivorship in an Asian specialist centre from Malaysia: A retrospective analysis

Circulating microRNAs and their role in the immune response in triple‑negative breast cancer (Review)

Contact Info

Product

Resources

About